A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

---

Kefeli U. (Yürütücü), Çabuk D., Üçüncü Kefeli A., Şikar Aktürk A.

Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje, 2023 - 2030

• Proje Türü: Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje
• Başlama Tarihi: Haziran 2023
• Bitiş Tarihi: Şubat 2030

Proje Özeti

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting